DOC-MEK
A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. The aim of this study was to assess the efficacy and safety of selumetinib combined with docetaxel as first-line treatment in patients with wild-type BRAF advanced melanoma.
Contact Information
- Email:
- octo-enquiries@oncology.ox.ac.uk
- Address:
-
OCTO
Department of Oncology, University of Oxford
ORCRB, Roosevelt Drive
Headington
Oxford
Oxfordshire
OX3 7DQ
England
Annual Statistics
| Year | Access Requests Received | Access Requests Approved | ||||
|---|---|---|---|---|---|---|
| Internal | External | Commercial | Internal | External | Commercial | |
| 2015 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2016 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2019 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A | N/A | N/A |